<DOC>
	<DOCNO>NCT03101930</DOCNO>
	<brief_summary>This project test principle hypothesis stable glucagon like peptide-1 ( GLP-1 ) analogues specific GLP1R-dependent beneficial effect vascular endothelial function , fibrinolysis inflammation obesity exceed benefit weight loss , genetic individual factor modulate GLP1R sensitivity modify effect analogue cardiovascular risk .</brief_summary>
	<brief_title>Cardiovascular Effects GLP-1 Receptor Activation</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Men woman , 2 . Age 18 65 year , 3 . FPG ( 100125 mg/dL ) , IGT ( twohour plasma glucose 140199 mg/dL ) , HbA1C 5.76.4 % 4 . BMI≥30 kg/M2 5 . The ability provide inform consent trialrelated activity . 1 . Diabetes type 1 type 2 , define FPG 126 mg/dL great , twohour plasma glucose 200 mg/dL great , use antidiabetic medication 2 . Resistant hypertension , define hypertension require administration three antihypertensive agent include diuretic achieve control 3 . Use spironolactone 4 . Known suspect allergy trial medication , excipients , related product . 5 . Family personal history multiple endocrine neoplasia type 2 ( MEN2 ) familial medullary thyroid carcinoma 6 . Personal history nonfamilial medullary thyroid carcinoma 7 . History pancreatitis 8 . Contraindications study medication , word specifically state product 's prescribing information 9 . Pregnancy breastfeed . Women childbearing potential require undergone tubal ligation use oral contraceptive barrier method birth control 10 . Subjects participated weightreduction program last six month whose weight increase decrease two kg precede six month 11 . Cardiovascular disease myocardial infarction within six month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure ( left ventricular hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy 12 . Treatment anticoagulants 13 . History serious neurologic disease cerebral hemorrhage , stroke , transient ischemic attack 14 . History presence immunological hematological disorder 15 . Diagnosis asthma require regular inhaler use 16 . Clinically significant gastrointestinal impairment could interfere drug absorption 17 . Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 3.0 x upper limit normal range ) 18 . Individuals eGFR &lt; 30 mL/min/1.73 m2 UACR &gt; 1000µg/mg , eGFR determine fourvariable Modification Diet Renal Disease ( MDRD ) equation , serum creatinine express mg/dL age year : eGFR ( mL/min/1.73m2 ) =186 • Scr1.154 • age0.203 • ( 1.212 black ) • ( 0.742 female ) 19 . Hematocrit &lt; 35 % 20 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult 21 . Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) 22 . Treatment lithium salt 23 . History alcohol drug abuse 24 . Treatment investigational drug one month precede study 25 . Previous randomization trial 26 . Mental condition render subject unable understand nature , scope possible consequence study 27 . Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>